Biotech IV Monitor

TFX — Teleflex Incorporated

$5.8B market cap · 0 upcoming readouts tracked

Clinical trial readout dates for Teleflex Incorporated, compiled from ClinicalTrials.gov, alongside the SEC filings where results are announced.

Market cap$5.8B
Cash & investments$430Mas of Sep 30, 2026
Recent 8-K filings1latest 2026-11-05

In progress, no date published

Phase 3 BiPASS (Illuccix)
Biopsy of the Prostate Avoidance Stratification Study
date not published
Ongoing

Cash position

Teleflex Incorporated reported $430M in cash, cash equivalents and marketable securities at Sep 30, 2026 (10-Q filed 2026-11-05). It reported net income of $927M for that quarter.

Recent SEC filings

8-K Reg FD Disclosure — often a data announcement2026-11-05

Companies working on similar indications

Discussion

No messages yet. If you follow TFX, you can start the conversation.
Track TFX in real time
See live implied volatility for TFX and 106 other biotechs, and get alerted when a readout lands.
🔔 Alert me on TFX
Contact — questions or corrections about TFX: dukeupt@gmail.com